Physician profile
Sarah Smith
NPI 1306637269
$1,176.67
in general payments reported to CMS, 2019-2025
13 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.67 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $234.31 | 2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $209.81 | 2025 | |
| Leo Pharma INC. | $175.72 | 2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $149.97 | 2025 | Nemluvio |
| Surgenex LLC | $126.12 | 2025 | Renograft, Pellograft, Surmatrix |
| Ucb, INC. | $77.38 | 2025 | Bimzelx |
| Smith+Nephew, INC. | $46.43 | 2025 | Stravix Pl |
| Almirall LLC | $34.40 | 2025 | Klisyri, Seysara |
| Novartis Pharmaceuticals Corporation | $30.72 | 2025 | |
| Paratek Pharmaceuticals, INC. | $23.86 | 2025 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $23.83 | 2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $22.64 | 2025 | Zoryve |
| Verrica Pharmaceuticals INC. | $21.48 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.